INTRODUCTION: COVID-19 has become a common threat to global human health and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some asymptomatic patients with early-stage lung cancer who have COVID-19 receive surgical treatment but develop severe pneumonia and other complications or even experience postoperative death, and they may have a worse prognosis compared with healthy individuals infected with COVID-19. However, there is no evidence that COVID-19 is a risk factor for lung cancer patients. This systematic review aims to evaluate the incidence and prognosis of COVID-19 in lung cancer patients and provide evidence-based medical support for clinical treatment. METHODS: We will search 6 medical databases to identify eligible studies published from the establishment of the database to the present. The quality of the included literature will be evaluated using the bias risk assessment tool in Cochrane 5.1.0, and a meta-analysis will be performed using Stata 14.0. Heterogeneity will be statistically assessed using χ2 tests. RESULTS: The study will integrate existing research findings to investigate the prevalence and severity rate of patients with lung cancer infected with SARS-CoV-2 and analyze the prognosis and adverse clinical outcomes in patients with or without COVID-19. CONCLUSION: The results of this study provide evidence to support whether COVID-19 is a risk factor for lung cancer and provide guidance for clinical prevention and treatment based on the evidence obtained in light of the unpredictable threat posed by COVID-19. ETHICS AND DISSEMINATION: Ethics approval is not required for this systematic review as it will involve the collection and analysis of secondary data. The results of the review will be reported in international peer-reviewed journals. PRORPERO REGISTRATION NUMBER: CRD42020195967.
INTRODUCTION: COVID-19 has become a common threat to global human health and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some asymptomatic patients with early-stage lung cancer who have COVID-19 receive surgical treatment but develop severe pneumonia and other complications or even experience postoperative death, and they may have a worse prognosis compared with healthy individuals infected with COVID-19. However, there is no evidence that COVID-19 is a risk factor for lung cancer patients. This systematic review aims to evaluate the incidence and prognosis of COVID-19 in lung cancer patients and provide evidence-based medical support for clinical treatment. METHODS: We will search 6 medical databases to identify eligible studies published from the establishment of the database to the present. The quality of the included literature will be evaluated using the bias risk assessment tool in Cochrane 5.1.0, and a meta-analysis will be performed using Stata 14.0. Heterogeneity will be statistically assessed using χ2 tests. RESULTS: The study will integrate existing research findings to investigate the prevalence and severity rate of patients with lung cancer infected with SARS-CoV-2 and analyze the prognosis and adverse clinical outcomes in patients with or without COVID-19. CONCLUSION: The results of this study provide evidence to support whether COVID-19 is a risk factor for lung cancer and provide guidance for clinical prevention and treatment based on the evidence obtained in light of the unpredictable threat posed by COVID-19. ETHICS AND DISSEMINATION: Ethics approval is not required for this systematic review as it will involve the collection and analysis of secondary data. The results of the review will be reported in international peer-reviewed journals. PRORPERO REGISTRATION NUMBER: CRD42020195967.
Authors: Julian Braun; Lucie Loyal; Marco Frentsch; Daniel Wendisch; Philipp Georg; Florian Kurth; Stefan Hippenstiel; Manuela Dingeldey; Beate Kruse; Florent Fauchere; Emre Baysal; Maike Mangold; Larissa Henze; Roland Lauster; Marcus A Mall; Kirsten Beyer; Jobst Röhmel; Sebastian Voigt; Jürgen Schmitz; Stefan Miltenyi; Ilja Demuth; Marcel A Müller; Andreas Hocke; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif Erik Sander; Andreas Thiel Journal: Nature Date: 2020-07-29 Impact factor: 49.962
Authors: Aditi P Singh; Abigail T Berman; Melina E Marmarelis; Andrew R Haas; Steven J Feigenberg; Jennifer Braun; Christine A Ciunci; Joshua M Bauml; Roger B Cohen; John C Kucharczuk; Lawrence N Shulman; Corey J Langer; Charu Aggarwal Journal: JCO Oncol Pract Date: 2020-05-26
Authors: Vikas Mehta; Sanjay Goel; Rafi Kabarriti; Balazs Halmos; Amit Verma; Daniel Cole; Mendel Goldfinger; Ana Acuna-Villaorduna; Kith Pradhan; Raja Thota; Stan Reissman; Joseph A Sparano; Benjamin A Gartrell; Richard V Smith; Nitin Ohri; Madhur Garg; Andrew D Racine; Shalom Kalnicki; Roman Perez-Soler Journal: Cancer Discov Date: 2020-05-01 Impact factor: 38.272
Authors: Peter J Mazzone; Michael K Gould; Douglas A Arenberg; Alexander C Chen; Humberto K Choi; Frank C Detterbeck; Farhood Farjah; Kwun M Fong; Jonathan M Iaccarino; Samuel M Janes; Jeffrey P Kanne; Ella A Kazerooni; Heber MacMahon; David P Naidich; Charles A Powell; Suhail Raoof; M Patricia Rivera; Nichole T Tanner; Lynn K Tanoue; Alain Tremblay; Anil Vachani; Charles S White; Renda Soylemez Wiener; Gerard A Silvestri Journal: Chest Date: 2020-04-23 Impact factor: 9.410